Literature DB >> 9263527

Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats.

K Sekine1, E Watanabe, J Nakamura, N Takasuka, D J Kim, M Asamoto, V Krutovskikh, H Baba-Toriyama, T Ota, M A Moore, M Masuda, H Sugimoto, H Nishino, T Kakizoe, H Tsuda.   

Abstract

The influence of bovine lactoferrin (bLF) on colon carcinogenesis was investigated in male F344 rats treated with azoxymethane (AOM). Following three weekly injections of AOM, the animals received 2 or 0.2% bLF for 36 weeks. No effects indicative of toxicity were noted, but significant reduction in both the incidence and number of adenocarcinomas of the large intestine was observed with both doses. Thus, the incidences of adenocarcinomas in the groups receiving 2% and 0.2% bLF were 15% and 25%, respectively, in contrast to the 57.5% control value (P < 0.01 and P < 0.05, respectively). The results indicate that bLF might find application for chemoprevention of colon cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263527      PMCID: PMC5921472          DOI: 10.1111/j.1349-7006.1997.tb00413.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  22 in total

Review 1.  Lactoferrin: a general review.

Authors:  P F Levay; M Viljoen
Journal:  Haematologica       Date:  1995 May-Jun       Impact factor: 9.941

2.  Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion.

Authors:  B S Reddy; B Simi; N Patel; C Aliaga; C V Rao
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

3.  Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.

Authors:  H Shau; A Kim; S H Golub
Journal:  J Leukoc Biol       Date:  1992-04       Impact factor: 4.962

4.  The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study.

Authors:  R S Kennedy; G P Konok; G Bounous; S Baruchel; T D Lee
Journal:  Anticancer Res       Date:  1995 Nov-Dec       Impact factor: 2.480

5.  Dietary milk proteins inhibit the development of dimethylhydrazine-induced malignancy.

Authors:  R Papenburg; G Bounous; D Fleiszer; P Gold
Journal:  Tumour Biol       Date:  1990

6.  Fermented dairy products, calcium, and colorectal cancer in The Netherlands Cohort Study.

Authors:  E Kampman; R A Goldbohm; P A van den Brandt; P van 't Veer
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

7.  Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice.

Authors:  J Bezault; R Bhimani; J Wiprovnick; P Furmanski
Journal:  Cancer Res       Date:  1994-05-01       Impact factor: 12.701

8.  Inhibition of tumor growth by dairy products.

Authors:  S Tsuru; N Shinomiya; M Taniguchi; H Shimazaki; K Tanigawa; K Nomoto
Journal:  J Clin Lab Immunol       Date:  1988-04

9.  Comparative epidemiology of cancer between the United States and Japan. A second look.

Authors:  E L Wynder; Y Fujita; R E Harris; T Hirayama; T Hiyama
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

10.  Dairy proteins protect against dimethylhydrazine-induced intestinal cancers in rats.

Authors:  G H McIntosh; G O Regester; R K Le Leu; P J Royle; G W Smithers
Journal:  J Nutr       Date:  1995-04       Impact factor: 4.798

View more
  17 in total

Review 1.  Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency.

Authors:  Denis E Corpet; Sylviane Taché
Journal:  Nutr Cancer       Date:  2002       Impact factor: 2.900

2.  Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice.

Authors:  M Iigo; T Kuhara; Y Ushida; K Sekine; M A Moore; H Tsuda
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 3.  The role of talactoferrin alpha in the treatment of non-small cell lung cancer.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Expert Opin Biol Ther       Date:  2010-09       Impact factor: 4.388

4.  Lactotransferrin expression is downregulated and affects the mitogen-activated protein kinase pathway in gastric cancer.

Authors:  Gengqiu Luo; Yanhong Zhou; Wei Yi; Hong Yi
Journal:  Oncol Lett       Date:  2015-03-03       Impact factor: 2.967

5.  Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo.

Authors:  Jeffrey S Wolf; Guoyan Li; Atul Varadhachary; Karel Petrak; Mark Schneyer; Daqing Li; Julina Ongkasuwan; Xiaoyu Zhang; Rodney J Taylor; Scott E Strome; Bert W O'Malley
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

6.  The survival of ingested lactoferrin in the gastrointestinal tract of adult mice.

Authors:  H Kuwata; T T Yip; K Yamauchi; S Teraguchi; H Hayasawa; M Tomita; T W Hutchens
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

7.  miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma.

Authors:  Min Deng; Qiurong Ye; Zailong Qin; Ying Zheng; Wei He; Hailin Tang; Yanhong Zhou; Wei Xiong; Ming Zhou; Xiaoling Li; Qun Yan; Jian Ma; Guiyuan Li
Journal:  Tumour Biol       Date:  2013-03-13

Review 8.  Prevention of carcinogenesis and cancer metastasis by bovine lactoferrin.

Authors:  Hiroyuki Tsuda; Katsumi Fukamachi; Jiegou Xu; Kazunori Sekine; Shigetoshi Ohkubo; Nobuo Takasuka; Masaaki Iigo
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2006-11-18       Impact factor: 3.493

9.  Lactoferrin deficiency promotes colitis-associated colorectal dysplasia in mice.

Authors:  Qiurong Ye; Ying Zheng; Songqing Fan; Zailong Qin; Nan Li; Anliu Tang; Feiyan Ai; Xuemei Zhang; Yanhui Bian; Wei Dang; Jing Huang; Ming Zhou; Yanhong Zhou; Wei Xiong; Qun Yan; Jian Ma; Guiyuan Li
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

Review 10.  Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?

Authors:  Klas Norrby
Journal:  APMIS       Date:  2013-10-26       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.